Fiche personne
Coordonnées
Plateforme de Biologie Hospitalo-Universitaire
Service d'Hématologie Biologique
2 rue Angélique Ducoudray
21000 DIJON
03 80 29 57 10
Territoire
Bourgogne
Statut
Hospitalo-Universitaire
Équipes/plateformes
Recherche
Expertises :
- Clinique:Hématologie
- Registre
Publications
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, Roussel M, Montes L, Cherel B, Chalopin T, Slama B, Chretien ML, Laribi K, Dingremont C, Roul C, Mariette C, Rigaudeau S, Calmettes C, Dib M, Tiab M, Vincent L, Delaunay J, Santagostino A, Macro M, Bourgeois E, Orsini-Piocelle F, Gay J, Bareau B, Bigot N, Vergez F, Lebreton P, Tabrizi R, Waultier-Rascalou A, Frenzel L, Le Calloch R, Chalayer E, Braun T, Lachenal F, Corm S, Kennel C, Belkhir R, Bladé JS, Joly B, Richez-Olivier V, Gardeney H, Demarquette H, Robu-Cretu D, Garderet L, Newinger-Porte M, Kasmi A, Royer B, Decaux O, Arnulf B, Belhadj K, Touzeau C, Mohty M, Manier S, Moreau P, Avet-Loiseau H, Corre J, Facon T
Nat Med. 2024 06 3;:
Early CAR-T Cells expansion is associated with prolonged PFS for patients with RRMM treated with ide-cel: a retrospective monocentric study.
Caillot L, Sleiman E, Lafon I, Chretien ML, Gueneau P, Payssot A, Pedri R, Lakomy D, Bailly F, Guy J, Quenot JP, Avet-Loiseau H, Caillot D
Transplant Cell Ther. 2024 03 6;:
Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma.
Touzeau C, Perrot A, Hulin C, Manier S, Macro M, Chretien ML, Karlin L, Escoffre M, Jacquet C, Tiab M, Leleu X, Avet-Loiseau H, Jobert A, Planche L, Corre J, Moreau P
Blood. 2024 02 23;:
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study.
Talbot A, Bobin A, Tabone L, Lambert J, Boccaccio C, Deal C, Petillon MO, Allangba O, Agape P, Arnautou P, Belkhir R, Cailleres S, Chaoui D, Chrétien ML, Decaux O, Schulmann S, Frenzel L, Gastaud L, Huart A, Hulin C, Karlin L, Laribi K, Le Calloch R, Lenain P, Macro M, Manier S, Montes L, Moreau S, Moreau P, Morel V, Norwood J, Piocelle FO, Perrot A, Pica GM, Rey P, Schmitt A, Stoppa AM, Tiab M, Touzeau C, Vidal V, Vignon M, Vincent L, Van De Wyngaert Z, Zarnitsky C, Kerbouche N, Paka P, Leleu X, Arnulf B, Avet-Loiseau H,
Haematologica. 2023 04 20;:
Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population-based study in France.
Atsou KM, Rachet B, Cornet E, Chretien ML, Rossi C, Remontet L, Roche L, Giorgi R, Gauthier S, Girard S, Böckle J, Wasse SK, Rachou H, Bouzid L, Poncet JM, Orazio S, Monnereau A, Troussard X, Mounier M, Maynadie M
Cancer Med. 2023 01 29;:
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S, Buisson L, Mahéo S, Do Souto Ferreira L, Pavageau L, Hulin C, Marolleau JP, Voillat L, Belhadj K, Divoux M, Slama B, Brechignac S, Macro M, Stoppa AM, Sanhes L, Orsini Piocelle F, Fontan J, Chretien ML, Demarquette H, Mohty M, Avet-Loiseau H, Corre J
Blood. 2022 11 14;:
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
Dumas PY, Raffoux E, Bérard E, Bertoli S, Hospital MA, Heiblig M, Desbrosses Y, Bonmati C, Pautas C, Lambert J, Orvain C, Banos A, Pasquier F, Peterlin P, Marchand T, Uzunov M, Frayfer J, Turlure P, Cluzeau T, Jourdan E, Himberlin C, Tavernier E, Villate A, Haiat S, Chretien ML, Carre M, Chantepie S, Vaida I, Wemeau M, Chebrek S, Guillerm G, Guièze R, Debarri H, Gehlkopf E, Laribi K, Marcais A, Santagostino A, Béné MC, Mineur A, Pigneux A, Dombret H, Récher C
Leukemia. 2022 11 14;:
In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations.
Lannes R, Samur M, Perrot A, Mazzotti C, Divoux M, Cazaubiel T, Leleu X, Schavgoulidze A, Chretien ML, Manier S, Adiko D, Orsini-Piocelle F, Lifermann F, Brechignac S, Gastaud L, Bouscary D, Macro M, Cleynen A, Mohty M, Munshi N, Corre J, Avet-Loiseau H
J Clin Oncol. 2022 11 7;:JCO2101987
Heterogeneity in long term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients.
Schavgoulidze A, Lauwers-Cances V, Perrot A, Cazaubiel T, Chretien ML, Moreau P, Facon T, Leleu X, Karlin L, Stoppa AM, Decaux O, Belhadj K, Arnulf B, Mohty M, Ariette CM, Fohrer-Sonntag C, Lenain P, Marolleau JP, Tiab M, Araujo C, Orsini-Piocelle F, Jaccard A, Roussel M, Benboubker L, Eveillard JR, Dib M, Divoux M, Attal M, Avet-Loiseau H, Corre J
Haematologica. 2022 09 29;:
Mortality and Major Cardiovascular Events among Patients with Multiple Myeloma: Analysis from a Nationwide French Medical Information Database.
Cottin Y, Boulin M, Doisy C, Mounier M, Caillot D, Chretien ML, Bodin A, Herbert J, Bonnotte B, Zeller M, Maynadié M, Fauchier L
Cancers (Basel). 2022 06 21;14(13):
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Roussel M, Lauwers-Cances V, Macro M, Leleu X, Royer B, Hulin C, Karlin L, Perrot A, Touzeau C, Chrétien ML, Rigaudeau S, Dib M, Nicolas-Virelizier E, Escoffre-Barbe M, Belhadj K, Mariette C, Stoppa AM, Araujo C, Doyen C, Fontan J, Kolb B, Garderet L, Brechignac S, Malfuson JV, Jaccard A, Lenain P, Borel C, Hebraud B, Benbrahim O, Dorvaux V, Manier S, Augeul-Meunier K, Vekemans MC, Randriamalala E, Chaoui D, Caers J, Chaleteix C, Benboubker L, Vincent L, Glaisner S, Zunic P, Slama B, Eveillard JR, Humbrecht-Kraut C, Morel V, Mineur P, Eisenmann JC, Demarquette H, Richez V, Vignon M, Caillot D, Facon T, Moreau P, Colin AL, Olivier P, Wuilleme S, Avet-Loiseau H, Corre J, Attal M
Blood. 2022 May 5;139(18):2747-2757
Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome.
Baumelou M, Payssot A, Row C, Racine J, Lafon I, Bastie JN, Chevreux S, Chrétien ML, Maynadié M, Caillot D, Guy J
Br J Haematol. 2022 Mar 11;:
All-oral triplet combination with ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible myeloma patients: final results of the phase 2 IFM study 2013-06.
Touzeau C, Perrot A, Roussel M, Karlin L, Benboubker L, Jacquet C, Mohty M, Facon T, Manier S, Chretien ML, Tiab M, Hulin C, Leleu X, Loiseau HA, Dejoie T, Planche L, Attal M, Moreau P
Haematologica. 2022 Feb 17;:
Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature.
Cazaubiel T, Leleu X, Perrot A, Manier S, Buisson L, Mahéo S, Do Souto Ferreira L, Lannes R, Pavageau L, Hulin C, Marolleau JP, Voillat L, Belhadj K, Divoux M, Slama B, Brechignac S, Macro M, Stoppa AM, Laurence S, Orsini Piocelle F, Fontan J, Chretien ML, DeMarquette H, Mohty M, Schavgoulidze A, Avet-Loiseau H, Corre J
Blood. 2022 Feb 16;:
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019.
Swan D, Hayden PJ, Eikema DJ, Koster L, Sauer S, Blaise D, Nicholson E, Rabin N, Touzeau C, Byrne J, Huynh A, Cornelissen JJ, Potter V, Forcade E, Parrish C, Gribben J, Chretien ML, Mielke S, Gedde-Dahl T, Reményi P, Tsirigotis P, Garcia Guiñón A, Beksac M, Schönland S, Yakoub-Agha I
Br J Haematol. 2022 Feb 15;:
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.
Bobin A, Kyheng M, Guidez S, Gruchet-Merouze C, Richez V, Duhamel A, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Perrot A, Roussel M, Jaccard A, Petillon MO, Belhadj-Merzoug K, Chretien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Moreau P, Avet-Loiseau H, Hulin C, Facon T, ,Leleu X
Leukemia. 2021 Oct 14;:
Comparison between tumour metabolism derived from F-FDG PET/CT and accurate cytogenetic stratification in newly diagnosed multiple myeloma patients.
Silva Y, Riedinger JM, Chrétien ML, Caillot D, Corre J, Guillen K, Cochet A, Tabouret-Viaud C, Loffroy R
Quant Imaging Med Surg. 2021 Oct;11(10):4299-4309
Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21).
Burlet B, Ramla S, Fournier C, Abrey-Recalde MJ, Sauter C, Chrétien ML, Rossi C, Duffourd Y, Ragot S, Buriller C, Tournier B, Chapusot C, Nadal N, Racine J, Guy J, Bailly F, Martin L, Casasnovas O, Bastie JN, Caillot D, Albuisson J, Broccardo C, Thieblemont C, Delva L, Maynadié M, Aucagne R, Callanan MB
Cold Spring Harb Mol Case Stud. 2021 Feb;7(1):
Self-management of immunomodulatory drug treatment in multiple myeloma patients.
Cransac A, Aho S, Cosme E, Chretien ML, Favennec C, Schreder L, Boutet M, Gueneau P, Giroud M, Caillot D, Boulin M
Eur J Cancer Care (Engl). 2020 Nov 6;:e13356
Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma.
Van de Wyngaert Z, Nerich V, Fouquet G, Chrétien ML, Caillot D, Azar N, Garderet L, Lenain P, Macro M, Bourhis JH, Belhocine R, Jaccard A, Karlin L, Bobin A, Moya N, Systchenko T, Gruchet C, Giraud C, Guidez S, Darras C, Princet I, Touzeau C, Moreau P, Hulin C, Deconinck E, Limat S, Leleu X,
Bone Marrow Transplant.. 2020 May 23;:
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial.
Boyle EM, Leleu X, Petillon MO, Karlin L, Doyen C, Demarquette H, Royer B, Macro M, Moreau P, Fostier K, Marie-Lorraine C, Zarnitsky C, Perrot A, Herbaux C, Poulain S, Manier S, Beauvais D, Walker BA, Wardell CP, Vincent L, Frenzel L, Caillon H, Susanna S, Dejoie T, Avet-Loiseau H, Mohty M, Facon T,
Br J Haematol. 2019 11;187(3):319-327
BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Cornillon J, Daguenet E, Bay JO, Chauchet A, Salles G, Contentin N, Nicolas-Virelizier E, Mercier M, Vallet N, Alexis M, Chrétien ML, Cluzeau T, Huynh A, Himberlin C, Dorvaux V, Amorim S, Lejeune C, de Latour RP, Gyan E
Ann. Hematol.. 2019 Aug;98(8):1973-1980
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.
Leleu X, Fouquet G, Richez V, Guidez S, Duhamel A, Machuron F, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Roussel M, Jaccard A, Pétillon MO, Belhadj-Merzoug K, Lepeu G, Chrétien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Attal M, Moreau P, Avet-Loiseau H, Hulin C, Facon T
Clin. Cancer Res.. 2019 Jul 15;25(14):4224-4230
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.
Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Fontan J, Voillat L, Demarquette H, Collet P, Rodon P, Sohn C, Lifermann F, Orsini-Piocelle F, Richez V, Mohty M, Macro M, Minvielle S, Moreau P, Leleu X, Facon T, Attal M, Avet-Loiseau H, Corre J
J. Clin. Oncol.. 2019 Jul 1;37(19):1657-1665
Adherence to immunomodulatory drugs in patients with multiple myeloma.
Cransac A, Aho S, Chretien ML, Giroud M, Caillot D, Boulin M
PLoS ONE. 2019 ;14(3):e0214446
B-ALL With t(5;14)(q31;q32); Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar -Rearranged B-ALL.
Fournier B, Balducci E, Duployez N, Clappier E, Cuccuini W, Arfeuille C, Caye-Eude A, Delabesse E, Bottollier-Lemallaz Colomb E, Nebral K, Chrétien ML, Derrieux C, Cabannes-Hamy A, Dumezy F, Etancelin P, Fenneteau O, Frayfer J, Gourmel A, Loosveld M, Michel G, Nadal N, Penther D, Tigaud I, Fournier E, Reismüller B, Attarbaschi A, Lafage-Pochitaloff M, Baruchel A
Front Oncol. 2019 ;9:1374
First case of proven invasive pulmonary infection due to Trichoderma longibrachiatum in a neutropenic patient with acute leukemia.
Sautour M, Chrétien ML, Valot S, Lafon I, Basmaciyan L, Legouge C, Verrier T, Gonssaud B, Abou-Hanna H, Dalle F, Caillot D
J Mycol Med. 2018 Dec;28(4):659-662
Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow.
Mazzotti C, Buisson L, Maheo S, Perrot A, Chretien ML, Leleu X, Hulin C, Manier S, Hébraud B, Roussel M, Do Souto L, Attal M, Avet-Loiseau H, Corre J
Blood Adv. 2018 11 13;2(21):2811-2813
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N
Blood. 2018 Sep 24;:
Ponatinib Evaluation And safety in Real Life CML patients failing ≥2 tyrosine kinase inhibitors: The PEARL observational study.
Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE
Exp. Hematol.. 2018 Sep 5;:
[Retrospective study of 25 cases of pulmonary mucormycosis in acute leukaemia].
Caillot D, Legouge C, Lafon I, Ferrant E, Pagès PB, Plocque A, Estivalet L, Valot S, Dalle F, Abou Hanna H, Chretien ML
Rev Mal Respir. 2018 May 10;:
Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma.
Gueneau P, Chretien ML, Cransac-Miet A, Aho LS, Lafon I, Favennec C, Guy J, Caillot D, Boulin M
Eur. J. Haematol.. 2018 May;100(5):518-525
HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis.
Sevin M, Kubovcakova L, Pernet N, Causse S, Vitte F, Villeval JL, Lacout C, Cordonnier M, Rodrigues-Lima F, Chanteloup G, Mosca M, Chrétien ML, Bastie JN, Audia S, Sagot P, Ramla S, Martin L, Gleave M, Mezger V, Skoda R, Plo I, Garrido C, Girodon F, de Thonel A
Nat Commun. 2018 Apr 12;9(1):1431
Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment.
Nakamura K, Kassem S, Cleynen A, Chrétien ML, Guillerey C, Putz EM, Bald T, Förster I, Vuckovic S, Hill GR, Masters SL, Chesi M, Bergsagel PL, Avet-Loiseau H, Martinet L, Smyth MJ
Cancer Cell. 2018 04 9;33(4):634-648.e5
Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.
Rossi C, Chrétien ML, Casasnovas RO
Target Oncol. 2018 Mar 20;:
Expressed fusion gene landscape and its impact in multiple myeloma.
Cleynen A, Szalat R, Kemal Samur M, Robiou du Pont S, Buisson L, Boyle E, Chretien ML, Anderson K, Minvielle S, Moreau P, Attal M, Parmigiani G, Corre J, Munshi N, Avet-Loiseau H
Nat Commun. 2017 12 1;8(1):1893
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
Duchmann M, Braun T, Micol JB, Platzbecker U, Park S, Pilorge S, Beyne-Rauzy O, Vey N, Sébert M, Gruson B, Dumas PY, Guieze R, Chretien ML, Laribi K, Chait Y, Legros L, Sahnes L, Hirsch P, Salanoubat C, Solary E, Fenaux P, Itzykson R
Blood Cancer J. 2017 05 12;7(5):e562
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.
Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, Boyle E, Chretien ML, Fontan J, Belhadj K, Brechignac S, Decaux O, Voillat L, Rodon P, Fitoussi O, Araujo C, Benboubker L, Fontan C, Tiab M, Godmer P, Luycx O, Allangba O, Pignon JM, Fuzibet JG, Legros L, Stoppa AM, Dib M, Pegourie B, Orsini-Piocelle F, Karlin L, Arnulf B, Roussel M, Garderet L, Mohty M, Meuleman N, Doyen C, Lenain P, Macro M, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H
Blood. 2016 Dec;128(25):2941-2948
Impact of pharmaceutical intervention on quality of life and coping strategies in patients with haematological malignancies.
Opsomer MA, Anota A, Noblot-Rossignol M, Bonnetain F, Pernot C, Chretien ML, Legouge C, Caillot D, Boulin M
Ann Pharm Fr. 2016 Nov;74(6):439-447
Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.
Garderet L, Beohou E, Caillot D, Stoppa AM, Touzeau C, Chretien ML, Karlin L, Moreau P, Fontan J, Blaise D, Polge E, Gueye MS, Ikhlef S, Marjanovic Z, Labopin M, Mohty M
Haematologica. 2016 Nov;101(11):1390-1397
CD45 phosphatase is crucial for human and murine acute myeloid leukemia maintenance through its localization in lipid rafts.
Saint-Paul L, Nguyen CH, Buffière A, Pais de Barros JP, Hammann A, Landras-Guetta C, Filomenko R, Chrétien ML, Johnson P, Bastie JN, Delva L, Quéré R
Oncotarget. 2016 10;7(40):64785-64797
Is It Time to Include CT "Reverse Halo Sign" and qPCR Targeting Mucorales in Serum to EORTC-MSG Criteria for the Diagnosis of Pulmonary Mucormycosis in Leukemia Patients?
Caillot D, Valot S, Lafon I, Basmaciyan L, Chretien ML, Sautour M, Million L, Legouge C, Payssot A, Dalle F
Open Forum Infect Dis. 2016 Oct;3(4):ofw190
Emergency and elective pulmonary surgical resection in haematological patients with invasive fungal infections: a report of 50 cases in a single centre.
Chretien ML, Legouge C, Pagès PB, Lafon I, Ferrant E, Plocque A, Favennec C, Estivalet L, Bottolier-Lemallaz E, Dalle F, Bastie JN, Bernard A, Caillot D
Clin. Microbiol. Infect.. 2016 Sep;22(9):782-787
Trim33/Tif1γ is involved in late stages of granulomonopoiesis in mice.
Chrétien ML, Legouge C, Martin RZ, Hammann A, Trad M, Aucagne R, Largeot A, Bastie JN, Delva L, Quéré R
Exp. Hematol.. 2016 Aug;44(8):727-739.e6
Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).
Stamatoullas A, Brice P, Gueye MS, Mareschal S, Chevallier P, Bouabdallah R, Nguyenquoc S, Francois S, Turlure P, Ceballos P, Monjanel H, Bourhis JH, Guillerm G, Mohty M, Biron P, Cornillon J, Belhadj K, Bonmati C, Dilhuydy MS, Huynh A, Bernard M, Chrétien ML, Peffault de Latour R, Tilly H
Bone Marrow Transplant.. 2016 Jul;51(7):928-32
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP
J. Clin. Oncol.. 2016 Jun;34(18):2125-32
Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis.
Roques M, Chretien ML, Favennec C, Lafon I, Ferrant E, Legouge C, Plocque A, Golfier C, Duvillard L, Amoureux L, Bastie JN, Maurin-Bernier L, Dalle F, Caillot D
Mycoses. 2016 Jun;59(6):383-90
Outbreak of Extended-Spectrum Beta-Lactamase Producing Enterobacter cloacae with High MICs of Quaternary Ammonium Compounds in a Hematology Ward Associated with Contaminated Sinks.
Chapuis A, Amoureux L, Bador J, Gavalas A, Siebor E, Chrétien ML, Caillot D, Janin M, de Curraize C, Neuwirth C
Front Microbiol. 2016 ;7:1070
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C
Oncotarget. 2015 Dec 8;6(39):42345-53
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
Chretien ML, Corre J, Lauwers-Cances V, Magrangeas F, Cleynen A, Yon E, Hulin C, Leleu X, Orsini-Piocelle F, Blade JS, Sohn C, Karlin L, Delbrel X, Hebraud B, Roussel M, Marit G, Garderet L, Mohty M, Rodon P, Voillat L, Royer B, Jaccard A, Belhadj K, Fontan J, Caillot D, Stoppa AM, Attal M, Facon T, Moreau P, Minvielle S, Avet-Loiseau H
Blood. 2015 Oct 29. pii: blood-2015-06-650242.
A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS, Mounier M, Roques M, Chretien ML, Boulin M
J Clin Pharm Ther. 2015 Aug;40(4):391-7
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
Hebraud B, Magrangeas F, Cleynen A, Lauwers-Cances V, Chretien ML, Hulin C, Leleu X, Yon E, Marit G, Karlin L, Roussel M, Stoppa AM, Belhadj K, Voillat L, Garderet L, Macro M, Caillot D, Mohty M, Facon T, Moreau P, Attal M, Munshi N, Corre J, Minvielle S, Avet-Loiseau H
Blood. 2015 Mar;125(13):2095-100
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelo
Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, Fruchart C, Stoppa AM, Gentil C, Wuilleme S, Huynh A, Hebraud B, Corre J, Chretien ML, Facon T, Avet-Loiseau H, Attal M
J Clin Oncol. 2014 Sep 1;32(25):2712-7
[A rare cause of pulmonary opacities: Lung localization of Waldenstrom's macroglobulinemia].
Monnet CM, Favrolt N, Bastie JN, Chretien ML, Benoit F, Rossi C, Camus P, Bonniaud P
Rev Mal Respir. 2014 Sep;31(7):632-5
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.
Chretien ML, Hebraud B, Cances-Lauwers V, Hulin C, Marit G, Leleu X, Karlin L, Roussel M, Stoppa AM, Guilhot F, Lamy T, Garderet L, Pegourie B, Dib M, Sebban C, Lenain P, Brechignac S, Royer B, Wetterwald M, Legros L, Orsini-Piocelle F, Voillat L, Delbrel X, Caillot D, Macro M, Facon T, Attal M, Moreau P, Avet-Loiseau H, Corre J
Haematologica. 2014 Jul;99(7):1236-8
Tif1gamma regulates the TGF-beta1 receptor and promotes physiological aging of hematopoietic stem cells.
Quere R, Saint-Paul L, Carmignac V, Martin RZ, Chretien ML, Largeot A, Hammann A, Pais de Barros JP, Bastie JN, Delva L
Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10592-7
Generic vancomycin products: Analysis of serum concentrations in patients with acute myeloid leukemia.
Monnier A, Malbranche C, Fagnoni P, Serge Aho L, Guerard P, Sgro C, Guignard MH, Croisier-Bertin D, Chavanet P, Chrétien ML, Caillot D, Boulin M
Ann Pharm Fr. 2014 May;72(3):178-83
Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, Chretien ML, Bastie JN, Brunotte F, Casasnovas RO
J Nucl Med. 2014 Apr;55(4):569-73
The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia?
Legouge C, Caillot D, Chrétien ML, Lafon I, Ferrant E, Audia S, Pagès PB, Roques M, Estivalet L, Martin L, Maitre T, Bastie JN, Dalle F
Clin. Infect. Dis.. 2014 Mar;58(5):672-8
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation.
Fouquet G, Hebraud B, Garciaz S, Stoppa AM, Roussel M, Caillot D, Chretien ML, Arnulf B, Szalat R, Garderet L, Benajiba L, Pegourie B, Regny C, Royer B, Caulier A, Touzeau C, Tessoulin B, Fermand JP, Facon T, Attal M, Loiseau HA, Moreau P, Leleu X
J Cancer. 2014 Mar 11;5(3):248-52
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chretien ML, Arnulf B, Szalat R, Garderet L, Benajiba L, Pegourie B, Regny C, Royer B, Caulier A, Stoppa AM, Garciaz S, Touzeau C, Chaleteix C, Fermand JP, Loiseau HA, Facon T, Attal M, Moreau P
Leukemia. 2013 Nov;27(11):2242-4
Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients.
Girodon F, Dutrillaux F, Broseus J, Mounier M, Goussot V, Bardonnaud P, Chretien ML, Maynadie M
Leukemia. 2010 Apr;24(4):900-3
